NEW YORK, April 9 (GenomeWeb News) - Activx Biosciences announced this week that it will apply its activity proteomics technology to characterize the activities of compounds for Foster City, Calif.-based Gilead Sciences.
Activx has similar deals already with Pfizer and Kyorin Pharmaceuticals.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.